Clinical Profile and Outcome of COVID 19 Patients at Tertiary Cardiovascular Center of Nepal.

Kunjang Sherpa1, Reeju Manandhar1, Chandra Mani Adhikari1, Murari Dhungana1, Dipanker Prajapati1, Roshan Raut1, Kiran Acharya1, Amrit Bogati1, Battu Kumar Shrestha2, Surakshya Joshi1, Prashant Bajracharya1, Prati Badan Dangol1, Puspa Marasaini3, Sujeet Rajbhandari1.

1Department of Cardiology, Shahid Gangalal National Heart Centre.
2Department of Anesthesiology, Shahid Gangalal National Heart Centre.
3Department of Nursing, Shahid Gangalal National Heart Centre.

Abstract

Background and Aims: Cardiovascular comorbidities are common in patients with COVID-19 and these patients are at higher risk of morbidity and mortality. It is not known if the presence of cardiovascular co-morbid conditions poses independent risk or whether this is mediated by other factors.

Methods: This is a retrospective follow up study done at Shahid Gangalal National Heart Centre (SGNHC). The main objective of this study was to study the clinical profile, baseline comorbidities, and outcome of cardiac patients and healthcare worker diagnosed with COVID 19. This study retrospectively evaluated case records of all cardiovascular disease (CVD) patients admitted at SGNHC with COVID 19 cases from 1st case diagnosed on July at SGNHC till September 2020.

Results: During this study period, 90 patients with COVID 19 with cardiovascular disease were admitted. The mean age of the study population was 52.3±19 years with 65.6% being male. Among the study population 52 (57.8%) had past history of cardiovascular disease, hypertension in 18 (20%) cases, diabetes in 8 (8.9%) cases. Among the patients with cardiovascular diagnosis, acute coronary syndrome was most common cardiovascular diagnosis in 23 (25.6% cases) followed by rheumatic heart disease in 21 (23.4%) cases, dilated cardiomyopathy in 7 (7.8% cases), ischemic cardiomyopathy with reduced ejection fraction (EF) in 7 (7.8%) cases, post coronary artery bypass graft (CABG) in 8 (8.9%), post valve replacement in 5 (5.5%), congenital heart disease in 3.3% cases and complete heart block in 3.3% cases. Most of the cases were symptomatic with moderate illness in 46.7% cases, mild illness in 41.4% cases and severe/critical illness in 11.1% cases. Among COVID patients with cardiovascular disease, the mortality was 11.1%.

Conclusion: Patients with cardiovascular disease with COVID 19 have more severe COVID 19 symptoms and has higher COVID 19 related death, so strict vigilance and early intervention is needed to improve its outcome.

Keywords: COVID 19; Nepal.

Introduction

A new respiratory tract infecting agent emerged in Wuhan city of China on December 2019 which was subsequently traced to be a novel corona virus outbreak on December 31, 2019.1 World Health Organization (WHO) gave the authorized name COVID-19 for this disease caused by SARS-Cov2, a novel virus genetically related to the coronavirus responsible for the 2003 SARS outbreak and in March 11, 2020 COVID-19 was declared a global health pandemic.2,3 Cardiovascular comorbidities are common in patients with COVID-19 and these patients are at higher risk of morbidity and mortality. It is not known if the presence of cardiovascular comorbid conditions pose independent risk or whether this is mediated by other factors.
Meta-analysis of 6 different studies on COVID-19 done in china showed that the proportions of hypertension, cardiovascular disease, and diabetes in patients with COVID-19 were 17.1%, 16.4%, and 9.7% respectively. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature showed hypertension followed by diabetes and cardiovascular diseases were the most common comorbidity seen in COVID-19 positive patients across major epicenters world-wide. Although having one or more comorbidity is linked to increased disease severity, no clear association was found between having these risk factors and increased risk of fatality. 

In Nepal, the first case was reported on 23 January 2020, a 32-year old Nepali man returning from Wuhan. Recently the outbreak of COVID-19 has created a nuisance in the health care system throughout the world and in our country too. Limited information has been available to describe the presenting characteristics and outcomes of cardiovascular patients requiring hospitalization with this illness. This study focus to study the clinical Profile, baseline comorbidities, and outcomes of the hospitalized patients and health care worker with COVID-19 in a tertiary cardiovascular center of Nepal at the initial stage of COVID pandemic in our country.

Methodology

This is a retrospective follow up study done at Shahid Gangalal National Heart Centre (SGNHC). The main objective of this study was to study the clinical profile, baseline comorbidities, and outcome of cardiac patients diagnosed with COVID 19. This study retrospectively evaluated case records of all cardiovascular disease (CVD) patients admitted at SGNHC with COVID 19 cases from 1st case diagnosed on July at SGNHC till September 2020. Formal approval was taken from Institutional review board of SGNHC.

The baseline data, age, sex, clinical severity of COVID, comorbidities, risk factor and outcome (recovered/mortality) were collected in preformed performa. For the outcome evaluation of the patient the hospital data were evaluated and in case of referred patient either the dedicated COVID hospital where patient was referred or the patient/patient party were contacted through telephone.

The study included all cardiovascular patients who were tested positive with RT PCR positive for SARS-CoV-2 before hospital admission. The study excluded the patient who were recovered from COVID 19 and who had persistently positive COVID 19 PCR test.

Clinical severity of COVID 19 were defined as per National Institute Of Health Covid 19 treatment guidelines for classification of COVID 19 cases: 1. Asymptomatic or Pre-symptomatic Infection: Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (e.g., polymerase chain reaction) or antigen test, but have no symptoms. 2. Mild Illness: Individuals who have any of the various signs and symptoms of COVID 19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal chest imaging 3. Moderate Illness: Individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SpO2 ) ≥94% on room air at sea level. 4. Severe Illness: Individuals who have respiratory frequency >30 breaths per minute, SpO2 <94% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FIO2) <300 or lung infiltrates >50%. 5. Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunctions. Comorbidities/risk factor and cardiovascular disease diagnosis based on documentation on the medical record data.

Data were entered into an electronic spread sheet (Microsoft Excel, Redmond) and the statistical analysis was done using the SPSS version 20 software. All parametric values were expressed as mean & nonparametric values were expressed in percentage (%).

Results

Covid 19 Patients with Cardiovascular Disease Baseline Characteristics

During this study period, 90 patients with COVID 19 with Cardiovascular disease were admitted. The mean age of the study population was 52.3±19 years with 65.6% being male. Among the study population, 52 (57.8%) had past history of cardiovascular disease, hypertension in 18 (20%) cases, Diabetes in 8 (8.9%) cases as shown in Table. 1.

Table 1: Baseline clinical characteristics of COVID 19 patients with cardiovascular diseases.

| Variable                                  | Frequency |
|-------------------------------------------|-----------|
| Age (Mean ± SD)                           | 52.3±19   |
| Sex (N/%)                                 |           |
| Male                                       | 59 (65.6%)|
| Female                                     | 31 (34.4%)|
| Past History of Cardiovascular Disease (N/%) | 52 (57.8%)|
| Smoking                                   | 28 (31.1%)|
| HTN                                       | 18 (20%)  |
| Diabetes Mellitus (N/%)                    | 8 (8.9%)  |
| COPD                                      | 2 (2.2%)  |

Among the patients with cardiovascular diagnosis, acute coronary syndrome was the most common cardiovascular diagnosis in 23 (25.6%) cases followed by rheumatic heart disease in 21 (23.4%) cases, dilated cardiomyopathy in 7 (7.8%) cases, ischemic cardiomyopathy with reduced ejection fraction (EF) in 7 (7.8%) cases, post Coronary Artery Bypass Graft (CABG) in 8 (8.9%), post valve replacement in 5 (5.5%), congenital heart disease in 3.3% cases, complete heart block in 3.3% cases and other cases as shown in Table 2.
Table 2: Cardiovascular disease diagnosis of COVID 19 patients.

| Cardiovascular Disease                                   | N=90 (100%) | Outcome (Number) |
|----------------------------------------------------------|-------------|------------------|
|                                                          |             | Recovered | Expired |
| Acute Coronary Syndrome                                  | 23 (25.6%)  |           |       |
| Acute Anterior Wall Myocardial Infarction (MI)           | 6           | 22        | 1      |
| Acute Inferior Wall MI                                   | 3           |           |       |
| Non ST-Elevation Myocardial Infarction (NSTEMI)          | 6           |           |       |
| Unstable Angina                                          | 8           |           |       |
| Rheumatic Heart Disease                                  | 21 (23.4%)  | 18        | 3      |
| Severe Mitral Stenosis (MS)                              | 12          |           |       |
| Severe Mitral Regurgitation (MR)                         | 6           |           |       |
| Severe Aortic Stenosis (AS)                              | 2           |           |       |
| Severe Aortic Regurgitation (AR)                         | 1           |           |       |
| Dilated Cardiomyopathy                                   | 7 (7.8%)    | 6         | 1      |
| Ischemic Cardiomyopathy with Reduced Ejection Fraction (EF) | 7 (7.8%)   | 4         | 3      |
| POST CABG                                                | 8 (8.9%)    | 6         | 2      |
| POST Mitral Valve Replacement (MVR)                      | 5 (5.5%)    | 5         |       |
| POST Double Valve Replacement (DVR)                      | 3           |           |       |
| POST Aortic Valve Replacement (AVR)                      | 1           |           |       |
| Congenital Heart Disease                                 | 3 (3.3%)    | 3         |       |
| Tetralogy of Fallot (TOF)                               | 1           |           |       |
| Total Anomalous Pulmonary Venous Connection (TAPVC)      | 1           |           |       |
| Atrial Septal Defect (ASD)                              | 1           |           |       |
| Complete Heart Block                                     | 3 (3.3%)    | 3         |       |
| Coronary Artery Disease-Triple Vessel Disease            | 3 (3.3%)    | 3         |       |
| Pericardial Effusion                                     | 2 (2.2%)    | 2         |       |
| Hypertensive Emergency                                  | 2 (2.2%)    | 2         |       |
| Degerative Valvular Heart Disease (VHD)                  | 2 (2.2%)    | 2         |       |
| Deep Vein Thrombosis                                    | 1 (1.1%)    | 1         |       |
| Pulmonary Embolism                                       | 1 (1.1%)    | 1         |       |
| Left Atrium (LA) Myxoma                                  | 1 (1.1%)    | 1         |       |
| Right Ventricle (RV) Cardiomyopathy                      | 1 (1.1%)    | 1         |       |
Most of the cases were symptomatic with moderate symptoms in 46.7% cases, mild in 41.4% cases and severe/critical in 11.1% cases as shown in figure 1. Among COVID patients with cardiovascular disease the mortality was found in 11.1% case as shown in figure 2.

**Figure 1:** Clinical severity of COVID 19 patients with cardiovascular disease.

![Clinical Severity](image1)

**Figure 2:** Outcome of COVID 19 patients with cardiovascular disease.

![Outcome Of COVID 19 patients with cardiovascular disease](image2)

**Discussion**

This retrospective study done at tertiary cardiac centre in Nepal enrolled patient with cardiovascular disease with COVID positive in which 57.8% had previously diagnosed CVD, 42.2% were diagnosed as new CVD during the hospital admission. Majority of the patients with cardiovascular disease were symptomatic with 46.7% having moderate illness and 11.1% having severe/critical illness similar to recent systematic review and meta-analysis by Kunihiro Matsushita et al which suggest that hypertension, diabetes, and CVD are independently associated with severe COVID-19.

Our study showed the mortality during this study period among the cardiovascular patients were high and mortality rate is 11.1%. The study done in various part of the world and including the meta-analysis showed higher mortality among patients with cardiovascular disease. In recent meta-analysis, cardiovascular symptoms or complications were registered in a considerable proportion (14.1%) of hospitalized COVID-19 patients and the case fatality rate was 9.6%.

The study done in Nepal assessing the clinical and epidemiological features of COVID-19 deaths in Nepal found that 61% of the deaths were associated with co-morbidities where cardiovascular diseases and diabetes in 31.2% cases similar to those reported in the other studies.

In another recent meta-analysis evaluating the mortality associated with cardiovascular disease in patients with COVID-19, patients with CVD and COVID-19 have a 4-fold higher risk of death. Diabetes and hypertension are also associated with higher mortality risk. Their study showed patients with CVD COVID-19 has higher mortality rate 24.2% and mortality rates were also higher in hospital registries (48.7%) compared to national reports (23.1%).

The mean age of study population was 52.3±19 years with 65.6% male patients similar to the others studies, indicating that COVID-19 commonly infects middle-aged and older population similar to the other studies done in various parts of the world in the early era of pandemic.

Our study showed that patients with CVD, older age and comorbidities have more severe covid symptoms and has higher COVID-19 related death compared to patients without CVD similar to the study done in China which showed CVD are independent risk factors for COVID-19 patient and COVID-19 patients with CVD were more severe and had higher mortality rate. The major limitation of the study is it was retrospective single centre study, we could not compare the mortality difference between COVID-19 positive patients with and without cardiovascular diseases. We also couldn’t assess the symptoms exacerbation whether it was due to COVID-19 or due to cardiovascular disease itself. A prospective study addressing the above issue may enlighten on the mortality difference between COVID-19 positive patients with and without cardiovascular diseases.

**Conclusion**

Although it was a single centre retrospective study, our study conducted at the beginning of COVID-19 pandemic including cohort of patients with cardiovascular disease with COVID-19 at the tertiary referral cardiac centre have highlighted the profile and outcome of COVID-19 patients with CVD and recommends that COVID-19 patients with CVD have more severe illness, and higher COVID-19 related deaths, so early intervention and vigilance should be taken.

**Acknowledgement**

The author acknowledges all the healthcare and supporting staffs of SGNHC who were dedicated to serve their duty during the COVID pandemic era.

**Conflict of Interest:** None

**References**

1. Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus out break in Wuhan, China. Int J Infect Dis. 2020; 91:264-266. https://doi.org/10.1016/j.ijid.2020.01.009

2. Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literaturere view. J Infect Public Health. 2020;13(5):667-673. https://doi.org/10.1016/j.jiph.2020.03.019

3. WHO. Novel Coronavirus-2020. Accessed 3 April 2020. https://www.who.int/csr/don/12-january-2020-novelcoronavirus-china/en/

4. Li, B, Yang, J, Zhao, F. et al. Prevalence and impact of...
cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109:531-538. https://doi.org/10.1007/s00392-020-01626-9

5. Thapa Bajgain K, Badal S, Bajgain BB et al. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature; American Journal of Infection Control 2020.06.213. https://doi.org/10.1016/j.ajic.2020.06.213

6. Bastola A, Sah R, Rodriguez-Morales AJ, et al. The first 2019 novel coronavirus case in Nepal. Lancet Infect Dis. 2020 Mar 1;20(3):279-80. https://doi.org/10.1016/S1473-3099(20)30067-0

7. Kunihiro M, Ning D, Minghao K, et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis Glob Heart. 2020; 15(1): 6 ; 2020 Sep 22. PMCID: PMC7546112. https://doi.org/10.5334/gh.814

8. Jolanda S, Salvatore RD, Giovanni SD, et al. Impact of cardiovascular risk profile on COVID-19 outcome. Ametanalysis: PLoS One. 2020; 15(12): e0243471. 2020 Aug 14. PMCID: PMC7428172. https://doi.org/10.1371/journal.pone.0243471

9. Panthee B, Dhungana S, Panthee N, et al. Clinical and epidemiological features of COVID-19 deaths in Nepal. New Microbe and New Infect 2020; 38: 100797. https://doi.org/10.1016/j.nnmi.2020.100797

10. De Souza WM, Buss LF, Candido DDS, et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat Hum Behav 2020;4:856-65.

11. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance-United States, January 22-May 30, 2020. MMWR 2020;69:759-65. https://doi.org/10.15585/mmwr.mm6924e2

12. SARS-CoV-2 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on September 7th, 2020. Italy: Istituto Superiore di Sanità;2020.

13. Cordero A, Santos García-Gallego C, Bertomeu-González V et al. Mortality associated with cardiovascular disease in patients with COVID-19. Rec. Cardioclinics. 2021 January-March;56(1):30-8. Epub 2020 Oct 26. PMCID: PMC7587172. https://doi.org/10.1016/j.rccl.2020.10.005

14. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. Chin Med J (Engl) 2020;133:1025-1031. https://doi.org/10.1097/CM9.0000000000000744

15. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239-1242. https://doi.org/10.1001/jama.2020.2648

16. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med 2020;382:1708-1720. https://doi.org/10.1056/NEJMoa2002032

17. Asghar MS, HaiderKazmi SI, Ahmed Khan N et al. Clinical Profiles, Characteristics, and Outcomes of the First 100 Admitted COVID-19 Patients in Pakistan: A Single-Center Retrospective Study in a Tertiary Care Hospital of Karachi. Cureus. 2020 Jun 20;12(6):e8712. https://doi.org/10.7759/cureus.c34

Nepalese Heart Journal 2021; Vol 18 (1): 7-11